Who bought IMVT stock in the last quarter?
Find the latest Immunovant, Inc. (IMVT) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors.
How much is immunovant stock worth?
Aug 03, 2021 · The stock currently trades at $7. Now what In the first half of the year, Immunovant had to stop two clinical trials for its drug IMVT-1401 …
Is the stock in the middle of a falling trend?
Apr 19, 2022 · Immunovant's stock was trading at $14.14 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, IMVT shares have decreased by 63.8% and is now trading at $5.12. View which stocks have been most impacted by COVID-19.
Why did IMVT stock drop?
IMVT, -0.20% plunged 49.8% to pace all premarket losers Tuesday, after the biopharmaceutical company said it has paused dosing in its phase 2b trial for IMVT-1401, a treatment for thyroid eye disease (TED).Feb 2, 2021
Is IMVT stock a good buy?
Out of 5 analysts, 0 (0%) are recommending IMVT as a Strong Buy, 2 (40%) are recommending IMVT as a Buy, 3 (60%) are recommending IMVT as a Hold, 0 (0%) are recommending IMVT as a Sell, and 0 (0%) are recommending IMVT as a Strong Sell.
Will IMVT go up?
Immunovant Inc (NASDAQ:IMVT) The 7 analysts offering 12-month price forecasts for Immunovant Inc have a median target of 12.00, with a high estimate of 16.00 and a low estimate of 7.00. The median estimate represents a +143.90% increase from the last price of 4.92.
Why is Immunovant stock down?
Why Shares of Immunovant Are Tanking Today Immunovant (NASDAQ: IMVT), a company developing a monoclonal antibody for the treatment of autoimmune diseases, is down almost 25% after receiving a cash injection of $200 million from Roivant Sciences.
Should I sell Immunovant?
10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Immunovant in the last twelve months. There are currently 1 sell rating, 5 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Immunovant stock.
Is Immunovant a buy right now?
10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Immunovant in the last year. There are currently 1 sell...
How has Immunovant's stock been impacted by Coronavirus (COVID-19)?
Immunovant's stock was trading at $14.14 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Orga...
When is Immunovant's next earnings date?
Immunovant is scheduled to release its next quarterly earnings announcement on Tuesday, June 7th 2022. View our earnings forecast for Immunovant .
How were Immunovant's earnings last quarter?
Immunovant, Inc. (NASDAQ:IMVT) issued its earnings results on Friday, February, 4th. The company reported ($0.36) earnings per share (EPS) for the...
What price target have analysts set for IMVT?
10 brokerages have issued 1-year price targets for Immunovant's shares. Their forecasts range from $7.00 to $20.00. On average, they anticipate Imm...
Who are Immunovant's key executives?
Immunovant's management team includes the following people: Dr. Peter Salzmann M.B.A. , M.D., CEO & Director (Age 53, Pay $1.02M) Ms. Pamela Yan...
Who are some of Immunovant's key competitors?
Some companies that are related to Immunovant include Twist Bioscience (TWST) , Iovance Biotherapeutics (IOVA) , ImmunityBio (IBRX) , Valneva (...
What other stocks do shareholders of Immunovant own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Immunovant investors own include salesforce.com (CRM) , N...
What is Immunovant's stock symbol?
Immunovant trades on the NASDAQ under the ticker symbol "IMVT."
An analyst note is extending yesterday's sell-off
What happened
Jason covers stocks for the Fool. He leans on his consulting background and executive experience in the human capital management and healthcare industries to offer analysis of individual companies.
So what
An analyst at Baird downgraded shares of Immunovant ( NASDAQ:IMVT) this morning after its former parent -- Roivant Sciences -- upped its stake in the company with a $200 million investment. The drop adds salt in the wound of the 26% collapse the shares experienced yesterday.
Now what
It's not the kind of news that usually tanks shares. But it wasn't the deal shareholders and analysts had expected. Earlier this year, Roivant had said it intended to make an outright purchase of Immunovant.
About Immunovant
In the first half of the year, Immunovant had to stop two clinical trials for its drug IMVT-1401 after participants developed high cholesterol levels. It intends to test the drug in other indications, and the investment -- which brings Roivant's stake up to 64% of Immunovant -- will allow that plan to go forward.
Immunovant (NASDAQ:IMVT) Frequently Asked Questions
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases.
Immunovant (IMVT) Reports Wider-Than-Expected Loss in Q2
10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Immunovant in the last twelve months. There are currently 1 sell rating, 5 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Immunovant stock.
Hedge Funds Are Dumping Immunovant, Inc. (IMVT)
Immunovant's (IMVT) earnings miss estimates in second-quarter fiscal 2022 (ended Sep 30, 2021). Focus remains on lead pipeline candidate IMVT-1401.
Quarter in Detail
A whopping number of 13F filings filed with U.S. Securities and Exchange Commission has been processed by Insider Monkey so that individual investors can look at the overall hedge fund sentiment towards the stocks included in their watchlists.
Pipeline Update
In the reported quarter, research and development (R&D) expenses were $18.6 million, up 30.9% from the year-ago quarter. The year-over-year increase was attributable to increase in contract manufacturing costs, driven by the expansion of the company’s clinical study programs for the treatment of autoimmune diseases.
Signals & Forecast
Immunovant is developing its lead pipeline candidate – IMVT-1401 – with an initial focus on the treatment of myasthenia gravis (“MG”), thyroid eye disease (“TED”) and warm autoimmune hemolyticanemia (“WAIHA”).
Support, Risk & Stop-loss
A buy signal was issued from a pivot bottom point on Monday, February 14, 2022, and so far it has risen 1.67%. Further rise is indicated until a new top pivot has been found. Some negative signals were issued as well, and these may have some influence on the near short-term development. The Immunovant, Inc.
Is Immunovant, Inc. stock A Buy?
Immunovant, Inc. finds support from accumulated volume at $5.46 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.
Insiders are very positive buying more shares than they are selling in Immunovant, Inc
Immunovant, Inc. holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.
Golden Star Signal
In the last 100 trades there were 85.95 million shares bought and 11.36 million shares sold. The last trade was done 25 days ago by Levine Mark S. who bough 383 thousand shares. The large amount of stocks bought compared to stocks sold indicate that the insiders believe there is a potential good upside.
Top Fintech Company
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star. This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!
What is immunovant? What is its purpose?
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
What is an X industry?
is a clinical-stage biopharmaceutical company, which develops monoclonal antibodies for the treatment of autoimmune diseases. It is developing IMVT-1401, a novel, fully-human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor. The company is developing IMVT-1401 as a fixed-dose subcutaneous injection for the treatment of autoimmune diseases mediated by pathogenic IgG antibodies.#N#The company is developing IMVT-1401 with an initial focus on the treatment of myasthenia gravis (MG), an autoimmune disease associated with muscle weakness; thyroid eye disease (TED), an autoimmune inflammatory disorder ...
Quarter in Detail
Pipeline Update
- Immunovant is developing its lead pipeline candidate – IMVT-1401 – with an initial focus on the treatment of myasthenia gravis (“MG”), thyroid eye disease (“TED”) and warm autoimmune hemolyticanemia (“WAIHA”). In February 2021, the company voluntarily paused dosing in ASCEND GO-2 – a phase IIb study in TED, and in ASCEND-WAIHA – a phase II study on IMVT-1401 in WAI…
Zacks Rank & Key Pick
- Immunovant currently carries a Zacks Rank #4 (Sell). A top-ranked stock in the biotech sector is Repligen Corporation RGEN which sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here. Repligen’s earnings estimates have been revised 15.7% upward for 2021 and 13.4% upward for 2022 over the past 60 days.
Zacks Names “Single Best Pick to Double”
- From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research SherazMian hand-picks one to have the most explosive upside of all. You know this company from its past glory days, but few would expect that it’s poised for a monster turnaround. Fresh from a successful repositioning and flus…